Evidence map›Paper›PMID 37138872›Full record

ArticleFrontiers in immunology2023

Succinylation modification provides new insights for the treatment of immunocompromised individuals with drug-resistant

Xianzhen Chen, Wenzhi Lei, Hui Meng, Yi Jiang, Sanli Zhang, Huyan Chen, Mingwei Du, Xiaochun Xue

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Dysregulation of protein succinylation and disease development.Frontiers in molecular biosciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Xianzhen ChenInstitute of Dermatology, Naval Medical University, Shanghai, China.
Wenzhi LeiInstitute of Dermatology, Naval Medical University, Shanghai, China.
Hui MengDepartment of Pharmacy, 905th Hospital of People's Liberation Army of China (PLA) Navy, Shanghai, China.
Yi JiangDepartment of Pharmacy, 905th Hospital of People's Liberation Army of China (PLA) Navy, Shanghai, China.
Sanli ZhangDepartment of Nephrology, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
Huyan ChenDepartment of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
Mingwei DuDepartment of Cardiology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Xiaochun XueDepartment of Pharmacy, 905th Hospital of People's Liberation Army of China (PLA) Navy, Shanghai, China.
People's Liberation Army 411 Hospital · CNHuashan Hospital · CNJinan Central Hospital · CNSecond Military Medical University · CNShanghai University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Invasive

Indexed as

AspergillosisAspergillus fumigatusAnimalsAntifungal AgentsHumansItraconazoleLysineMiceTriazolesAntifungal AgentsItraconazoleLysineTriazolesAspergillus fumigatusdrug resistanceimmunocompromisedmacrophagesuccinylation

Identifiers

PMID37138872
PMCPMC10150703
OpenAlexW4366084665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.